Smartkarma Daily Briefs

• Intel is pinning much hope on the success of the AIPC, a venture in which they are tied at the hip with Microsoft, which calls it a CoPilot+ PC
• The AIPC/CoPilot+ PC concept is struggling to gain traction. They will sell in volume, but only because buyers will have limited alternatives available. Ultimately, we see AIPCs cannibalising non-AIPCs
• Intel’s performance was underwhelming to say the least, but at the same time, not in the least bit surprising. Earnings coming on January 23. 

• LUNA stock faced a 57% decline due to Nasdaq delisting notice, with trading volume 25 times the average.
• White Hat Capital Partners invested $50m in December 2023 and increased the loan facility to $30m in October 2024.
• Luna Innovations specializes in fiber optic sensing solutions, with notable contracts in aerospace, automotive, and oil & gas industries.

• The Insight presents two S&P 500 INDEX (SPX INDEX) options strategies for 2025. Call overwriting can generate premium income and potentially enhance returns in a choppy but mildly positive market.
• The second strategy is a Risk Reversal, using the proceeds from a short call to buy a protective put option, providing downside protection while still allowing for some upside potential.
• Both strategies are designed to align with the expected market conditions, considering factors such as inflation, economic growth, and market volatility.

• The Fed injected some volatility into the market after their December meeting, as they noted an uncertain inflation outlook and the SEP less expected rate cuts for 2025.
• We discussed in our latest report (12/23/24 ETF Pathfinder), and continue to believe, that this is a buying opportunity.
• Market dynamics remain risk-on, the SPX remains above 5850 (a key support level we have discussed since late-November), mid-caps (IJH) and small-caps (IWM) are above supports at $61.50 and $218

• Amer Sports, owned by ANTA Sports, is focusing on expanding in the Chinese market, particularly through the Arc’teryx brand
• New store openings in China are expected to drive revenue and EBIT growth for Amer Sports
• Arc’teryx faces stiff competition in the outdoor apparel market, with its technical attributes not standing out as much as expected, despite surpassing Canada Goose in revenue and having a strong presence in China

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• We are reiterating our Buy rating, $20 price target and projections for Lands’ End as we look forward to 2025.
• We believe, after an impressive return to profitability in FY24, Lands’ End management is poised to continue to build on their winning business model drivers (improved product, marketing and customer reach, Outfitters, international and licensing) to drive further upside into FY25 and amply demonstrate the power of Lands’ End to leverage a quintessential and trusted American brand to drive compelling returns.
• As such, we reiterate our Buy rating and $20 price target for LE.

• Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.
• Preclinical tests showed that the company’s signature therapy, Telomir-1, appeared to correct a rare genetic condition that shortens life span, continuing a string of positive test announcements.

• CABO’s stock has dropped by 45% since the previous writeup due to declining revenue and EBITDA in the fourth quarter of 2022
• Financial leverage and a large short interest have contributed to investor loss of confidence in CABO
• The writer suggests that the decreased stock price presents a better investment opportunity in CABO now

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• We are reiterating our Buy rating, $23 price target and projections for Guess?
• as we look forward to 2025.
• We believe, after their first acquisition, continued European expansion and investor worries over weak domestic performance in 2024, 2025 will a year for the company to begin to leverage their prior investments and shift the investment thesis forward to top line and margin expansion.

• We are reiterating our Buy rating, $40 price target and projections for JAKKS Pacific, as we believe, driven by strong Holiday movie content and among the easiest comparisons in recent history, the company is poised to register strong 1H25 results.
• More importantly, we believe, potential China tariffs excluded, JAKKS is building a base of key core items/categories (i.e. The Simpsons, Sonic, skateboards and Spring outdoor products) and international expansion, which will create the ability for JAKKS to register visible and impressive overall top and bottom line returns.
• Further, we also believe in 2025, given the company’s impressive financial position (no debt, approximately $2 per share in cash), JAKKS will begin to return capital to shareholders.